Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations

  title={Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations},
  author={A. Hoos},
  journal={Nature Reviews Drug Discovery},
  • A. Hoos
  • Published 2016
  • Medicine
  • Nature Reviews Drug Discovery
  • Since the regulatory approval of ipilimumab in 2011, the field of cancer immunotherapy has been experiencing a renaissance. This success is based on progress in both preclinical and clinical science, including the development of new methods of investigation. Immuno-oncology has become a sub-specialty within oncology owing to its unique science and its potential for substantial and long-term clinical benefit. Immunotherapy agents do not directly attack the tumour but instead mobilize the immune… CONTINUE READING
    284 Citations
    Oncolytic viruses—immunotherapeutics on the rise
    • 40
    Immuno-Oncology: Emerging Targets and Combination Therapies
    • 109
    • PDF
    Future perspectives in cancer immunotherapy.
    • 25
    • PDF
    Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
    • 96
    Cancer immunotherapy: challenges and clinical applications
    • 9
    The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies
    • 25


    Big opportunities for small molecules in immuno-oncology
    • 211
    • PDF
    Cancer immunotherapy comes of age
    • 2,318
    • PDF
    The immuno-oncology framework
    • 13
    The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
    • 239
    Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
    • 5,477
    • PDF
    Cancer immunotherapy
    • 421